Laurys BOUDIN

Dr. Laurys BOUDIN

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
LBLaurys BOUDIN
Laurys BOUDIN
FJFrédéric Janvier
Frédéric Janvier
OBOlivier Bylicki
Olivier Bylicki
FDFabien Dutasta
Fabien Dutasta

1 January 2021 in OncoImmunology
Verified
Journal Article
Open access
FBFrançois Bertucci
François Bertucci
LBLaurys BOUDIN
Laurys BOUDIN
PFPascal FINETTI
Pascal FINETTI
CBChristophe Van Berckelaer
Christophe Van Berckelaer
PDPeter Van Dam
Peter Van Dam
Emilie MamessierEmilie Mamessier
Emilie Mamessier
Background. Anti-PD1/PDL1 immune checkpoint inhibitors (ICIs) showed promising results in breast cancer, and exploration of additional actionable immune checkpoints is ongoing. Inflammatory breast cancer (IBC) is an aggressive form of disease, the immune tumor microenvironment (TME) of which is poorly known. We aimed at providing the first comprehensive immune portrait of IBCs. Methods. From the gene expression profiles of 137 IBC and 252 non-IBC clinical samples, we measured the fractions of 22 immune cell types, expression of signatures associated with tertiary lymphoid structures (TLS) and with the response to ICIs (T cell-inflamed signature: TIS) and of 18 genes coding for major actionable immune checkpoints. The IBC/non-IBC comparison was adjusted upon the clinicopathological variables. Results. The immune profiles of IBCs were heterogeneous. CIBERSORT analysis showed profiles rich in macrophages, CD8+ and CD4 + T-cells, with remarkable similarity with melanoma TME. The comparison with non-IBCs showed significant enrichment in M1 macrophages, γδ T-cells, and memory B-cells. IBCs showed higher expression of TLS and TIS signatures. The TIS signature displayed values in IBCs close to those observed in other cancers sensitive to ICIs. Two-thirds of actionable immune genes (HAVCR2/TIM3, CD27, CD70, CTLA4, ICOS, IDO1, LAG3, PDCD1, TNFRSF9, PVRIG, CD274/PDL1, and TIGIT) were overexpressed in IBCs as compared to normal breast and two-thirds were overexpressed in IBCs versus non-IBCs, with very frequent co-overexpression. For most of them, the overexpression was associated with better pathological response to chemotherapy. Conclusion. Our results suggest the potential higher vulnerability of IBC to ICIs. Clinical trials.

25 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Juliette THARIATJuliette THARIAT
Juliette THARIAT
LBLaurys BOUDIN
Laurys BOUDIN
OLOlivier Loria
Olivier Loria
ANAnh-Minh Nguyen
Anh-Minh Nguyen
Laurent KodjikianLaurent Kodjikian
Laurent Kodjikian
Thibaud MathisThibaud Mathis
Thibaud Mathis
Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient.

23 March 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
LBLaurys BOUDIN
Laurys BOUDIN
MPMatthieu Patient
Matthieu Patient
EREmilie Roméo
Emilie Roméo
JBJean-Sébastien Bladé
Jean-Sébastien Bladé
JJJean-Pierre de Jauréguiberry
Jean-Pierre de Jauréguiberry
(2018). Efficacy of ibrutinib as first-line treatment of tumoral Bing–Neel syndrome. Leukemia & Lymphoma. Ahead of Print.

14 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
LBLaurys BOUDIN
Laurys BOUDIN
JMJean-Baptiste Morvan
Jean-Baptiste Morvan
Juliette THARIATJuliette THARIAT
Juliette THARIAT
DMDenis Métivier
Denis Métivier
PMPierre Yves Marcy
Pierre Yves Marcy
DDDavid Delarbre
David Delarbre
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease. Thyrosine kinase inhibitors, especially lenvatinib and immune checkpoint inhibitors such as pembrolizumab, are emerging drugs for ATC. Few studies have reported the efficacity of pembrolizumab and lenvatinib association, resulting in its frequent off-label use. In this review, we discuss rationale efficacy and safety evidence for the association of lenvatinib and pembrolizumab in ATC. First, we discuss preclinical rationale for pembrolizumab monotherapy, lenvatinib monotherapy and synergistic action of pembrolizumab and lenvatinib in the metastatic setting. We also discuss clinical evidence for immunotherapy and pembrolizumab in ATC through the analysis of studies evaluating immunotherapy, lenvatinib and pembrolizumab lenvatinib association in ATC. In addition, we discuss the safety of this association and potential predictive biomarkers of efficiency.

26 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JMJean-Baptiste Morvan
Jean-Baptiste Morvan
LBLaurys BOUDIN
Laurys BOUDIN
DMDenis Métivier
Denis Métivier
DDDavid Delarbre
David Delarbre
EBEdouard Bouquillon
Edouard Bouquillon
PMPierre Yves Marcy
Pierre Yves Marcy
Internal jugular vein tumor thrombus is an extremely rare condition in thyroid carcinoma, but it does exist. Correlated with greater aggressiveness with a higher incidence of distant metastases at diagnosis and a higher recurrence rate, this important prognostic element should be systematically investigated by ultrasound operators in all patients presenting with thyroid carcinoma. The patient’s follow-up must be careful. This can be a trap that surgeons must look for in their preoperative checklist. We report the case of a 58-year-old woman with an IJV thrombus associated with multiple bone metastases. She underwent successful surgical treatment, and postoperative pathology showed a poorly differentiated follicular carcinoma of the thyroid and a tumor thrombus in the internal jugular vein.